One Versus Two Months Anticoagulation After Catheter Ablation for Atrial Fibrillation in Patients Who Were Not Indicated for Long-Term OAC: A Pilot Randomized Controlled Trial (The REDUCIBLE Trial).

Save

Background and Objectives

Even low-risk atrial fibrillation (AF) patients usually continue anticoagulant therapy for several months after the procedure. However, there is no solid evidence supporting this practice. The REDUCIBLE trial is designed to compare the outcomes of conventional 2- versus 1-month oral anticoagulant (OAC) therapy following successful catheter ablation (CA) in men with a CHA2DS2-VASc score of ≤1 and women with ≤2, where long-term OAC is not recommended.

Methods

In this pilot study, patients undergoing CA for drug-refractory paroxysmal AF were randomly divided into 2 groups. One group received OAC for 1 month, whereas the other received it for 2 months. The primary outcome was the incidence of stroke and systemic embolism within 1 year after ablation.

Results

A total of 220 patients were enrolled and randomly assigned to 2 groups. Baseline characteristics were similar between the groups. The AF recurrence-free survival (RFS) rate was similar (76.9% vs.

77.7%, p=0.98). During the blanking period, AF RFS was also similar (92.5% vs. 92.9%, p=0.98).

No ischemic stroke or systemic embolism occurred in either group during 1-year follow-up. One patient in the 1-month group experienced a minor bleeding event when anticoagulants were not taken (7 months after ablation).

Conclusions

This study found that a single month of OAC post-ablation did not significantly elevate the risk of stroke or systemic embolism in low-risk patients. Nonetheless, a larger sample size would be necessary to achieve the statistical power for definitive conclusions. Future larger prospective clinical trials are needed to address this question comprehensively.

Trial Registration

ClinicalTrials.gov Identifier: NCT03573037

INTRODUCTION

Atrial fibrillation (AF) is the most common sustained arrhythmia, with its incidence and prevalence increasing. In the US, it is estimated that between 6–12 million people will suffer from this condition by 2050, and in Europe, the number is projected to reach 17.9 million by 2060.1) Individuals with AF may face an approximately 3.5-fold increased risk of mortality, mainly due to an elevated risk of stroke, systemic embolic events, and ventricular dysfunction.2)

Catheter ablation (CA) has proven to be an effective treatment strategy, improving clinical symptoms by reducing the burden of AF and the need for cardiovascular hospitalizations.3) A CHA2DS2-VASc score of 1 corresponds to a stroke rate of 1.20 in the ATRIA study and 2.4 in a Swedish cohort.4)5) Current guidelines recommend maintaining oral anticoagulation for at least 2 months post-successful CA, regardless of CHA2DS2-VASc score or maintenance of sinus rhythm. However, the rationale for this duration of oral anticoagulant (OAC) post-ablation and the specific endpoint remains undetermined. OACs are associated with an increased risk of major bleeding events, which can be life-threatening.6)

The decision to continue OAC post-ablation involves weighing the complex interplay between risk and benefit, considering bleeding risks, and the prevention of cardio-embolic strokes. A CHA2DS2-VASc score ≤2 may not benefit from continued OAC usage, yet faces the same risk of bleeding.7) It is reported that the risk of bleeding peaks within the first 3 months. Under current guidelines, patients with a very low risk of stroke (i.e., CHA2DS2-VASc score 0 or 1) and those maintaining sinus rhythm are advised to continue OAC for at least 2 months post-ablation, despite a lack of supporting evidence.8) Although there is a modestly increased risk of periprocedural stroke or transient ischemic attack (TIA) compared to cardioversion, the long-term risk of non-TIA stroke is lower in those undergoing ablation.9)

Our prospective randomized trial (Re-Evaluation of the Duration of Anticoagulation in the Blanking Period following AF ablation, REDUCIBLE trial) compares the safety and efficacy of conventional 2-month OAC therapy versus a 1-month regimen post-successful CA in males with a CHA2DS2-VASc score ≤1 and females ≤2, who are not candidates for long-term OAC.

METHODS

Study design and population

The REDUCIBLE trial is a prospective, randomized clinical study wherein patients undergoing CA for drug-refractory paroxysmal AF were assigned randomly. We included only patients with paroxysmal AF and excluded those with persistent AF. Patients’ risk profiles were evaluated using the CHA2DS2-VASc score.

Included were patients with a CHA2DS2-VASc score ≤1 in men and ≤2 in women. Patients with mitral stenosis or prosthetic heart valves were excluded as they required long-term OAC regardless of their CHA2DS2-VASc score. Additionally, those presenting an intracardiac thrombus during evaluation were excluded.

During the blanking period following CA, one group received OAC for 1 month, while another received it for 2 months. The primary endpoint was the occurrence of stroke and systemic embolism during the year post-ablation (REDUCIBLE trial, ClinicalTrials.gov number, NCT03573037).

Electrophysiology study and ablation strategy

Prior to the procedure, patients underwent transesophageal echocardiography or cardiac computed tomography to screen for intracardiac thrombi. An electrophysiology study was carried out under intravenous sedation with bilevel-positive airway pressure support, as previously described.10) Intracardiac electrograms were filtered between 30 and 500 Hz using an amplifier system integrated in the Prucka Cardio Lab System (GE Healthcare, Milwaukee, WI, USA). Both the CARTO (Biosense Webster, Diamond Bar, CA, USA) and the Ensite NavX (St.

Jude Medical, St. Paul, MN, USA) systems were employed for detailed electroanatomical mapping. Dual trans-septal access was utilized; a circular mapping catheter was introduced into the left atrium via a long sheath (Preface; Biosense Webster), and an ablation catheter was advanced through a second trans-septal sheath (SL1; St.

Jude Medical). CA was performed using a 4-mm open irrigated catheter (Coolflex; St. Jude Medical) without halting warfarin therapy during the procedure.

Pulmonary vein isolation (PVI) included ablation of the left- and right-side ipsilateral pulmonary veins and the carina lines. If atrial arrhythmias persisted post-PVI, additional substrates were targeted. Some patients also underwent roof line and perimitral isthmus line ablations at the discretion of the operator.

Radiofrequency (RF) energy settings ranged from 25 to 40 W, with the upper-temperature limit set at 45°C and a saline irrigation rate of 15 mL/min. The RF energy was delivered using a dragging technique until a reduction in the maximal local electrogram amplitude of ≥80% was achieved. Anticoagulation during the procedures involved an intravenous heparin regimen; a 100 U/kg heparin bolus was administered immediately prior to the trans-septal puncture, followed by either continuous or intermittent infusion, adjusted to maintain an activated coagulation time between 300 and 400 seconds.

Anticoagulation protocol

All enrolled patients received anticoagulation therapy with either warfarin or direct oral anticoagulants (DOACs) for a minimum of four weeks prior to the ablation procedure.11) Outpatient monitoring of the international normalized ratio (INR) was conducted 1 to 2 weeks before the procedure to ensure that INR levels were within the therapeutic range (2 to 3). Warfarin therapy was not interrupted and was administered on the evening of the procedure as per the patient’s regular dosing schedule. Those prescribed DOACs omitted two doses (for those on dabigatran or apixaban) or one dose (for those on rivaroxaban) immediately prior to the procedure, with resumption of DOAC therapy on the evening of the same day.

An intravenous unfractionated heparin (UFH) bolus of 100 U/kg was administered immediately before transseptal puncture for all patients (initial dose). The heparin dosage was adjusted to achieve and maintain an optimal activated clotting time (ACT) (300 to 400 seconds), with monitoring every 30 minutes during the procedure. ACTs were gauged using a commercial analyzer (Hemochron Response; ITC, Edison, NJ, USA).

Following the initial ACT measurement, subsequent UFH boluses were given every 30 minutes to maintain the desired ACT level in the intermittent infusion group. The dosage of UFH was determined based on prior experience. Post-2016, based on the findings of the COHERE trial,11) heparin was almost universally administered via continuous infusion in most patients, starting at an initial maintenance dose ranging from approximately 25 to 100 U/kg/h after the first ACT measurement and adjusting the infusion rate based on subsequent ACT assessments.

In the intermittent group, additional heparin boluses ranged from 1,000 to 4,000 U, while adjustments to the infusion rate in the continuous group varied between decreases and increases of 500 to 2,000 U/h.

Post-ablation monitoring and follow-up

All patients underwent post-ablation follow-up at 3, 6, and 12 months using 24-hour Holter monitoring. Additional monitoring occurred if patients reported symptoms indicative of tachyarrhythmia. With the exception of those experiencing a documented recurrence of atrial tachyarrhythmia, antiarrhythmic medications were discontinued after the blanking period.

The recurrence of AF was established if any sustained atrial tachyarrhythmia was recorded for more than 30 seconds, occurring 30 seconds after a 3-month blanking period.

The endpoint of the study

The study designated ischemic stroke within 1 year following post-CA as the endpoint. An ischemic stroke was classified as a sudden onset of a focal neurological deficit that lasted for over 24 hours.12)

Statistical analysis

Continuous variables were presented as means ± standard deviation, while categorical data were expressed in percentages. The comparison of continuous variables between the two groups was conducted using the independent samples Student t-test. The χ2 analysis was utilized to compare categorical variables.

A 2-tailed p-value of less than 0.05 was considered to indicate statistical significance. This study was a pilot randomized trial designed to test the hypothesis that shortening anticoagulant therapy duration to 1 month may be safe for low-risk (CHA2DS2-VASc score 0 to 1 point) patients, in the absence of objective evidence for anticoagulant therapy shortening strategies. The sample size was not calculated based on statistical power, but was set based on the number of patients who could be recruited in the actual clinical trial over 3 years.

This was because randomization and shortening treatment itself carry clinical risks in the absence of evidence for shortening anticoagulant therapy. This trial aimed to generate pilot data for sizing a future non-inferiority randomized controlled trial, rather than to demonstrate statistical superiority or equivalence.

RESULTS

Baseline characteristics and thromboembolic risk

Patients were prospectively enrolled between March 2015 and December 2019. Patients who underwent successful CA for AF were randomly allocated into 2 groups: those continuing OACs for 1 month and for 2 months. The baseline characteristics were similar in both groups (Table 1).

There was no significant difference in procedural characteristics (Table 2). The first group, which comprised 108 patients prescribed OAC for 1 month, had an average age of 58.3±8.0 years, with 82% being male. Of these participants, 35 (32.4%) had a CHA2DS2-VASc score of 0, 62 (57.4%) had a score of 1, and 11 (10.2%) had a score of 2.

The second group included 112 patients, with an OAC duration of two months, an average age of 59.1±9.4 years, and 78.6% male. Within this group, 28 (25.0%) had a CHA2DS2-VASc score of 0, 73 (65.2%) a score of 1, and 11 (9.8%) a score of 2. There was no difference between the 2 groups in the distribution of anticoagulant (with warfarin, 16.7% [18/108] vs.

17.9% [20/112], p=0.87). There was no significant difference in antiarrhythmic drug use after the procedure between the 2 groups (23.1% [25/108] vs. 23.2% [26/112], p=0.99).

Follow-up and clinical outcomes

Nearly all patients were followed for up to 1 year post-CA, although three patients (1 from the 1-month group and 2 from the 2-month group) were lost to follow-up. At the end of follow-up (1 year), the AF recurrence-free survival (RFS) rate was 76.9% in the 1-month group and 77.7% in the 2-month group (p=0.98). During the blanking period (within 3 months), AF RFS was 92.5% in the 1-month group and 92.9% in the 2-month group (p=0.98).

There was no significant difference in the early recurrence rate and the one-year recurrence rate. No ischemic stroke or systemic embolism occurred in either group during 1-year follow-up. Minor bleeding (n=1) occurred among patients assigned to the one-month group when anticoagulants were not taken (7 months after ablation).

The bleeding event was attributed to hemorrhoids, occurred only once, and was not associated with a decrease in hemoglobin level. The patient recovered with conservative management. No mortality events were observed in this study population during the follow-up period (1 year).

The study flow chart is presented in Figure 1.

DISCUSSION

In this prospective randomized trial, we found no significant risk associated with 1-month OAC therapy following CA for AF in individuals with a CHA2DS2-VASc score ≤1 in men and ≤2 in women, who were not indicated for long-term OAC.

Current guidelines suggest that the decision for long-term OAC therapy should be based on the presence of CHA2DS2-VASc stroke risk factors, rather than the rhythm status.6) There is a consensus that OAC therapy ought to be maintained for at least 2 months post-AF ablation.6)13) However, OAC use is not without risks. In recent clinical trials, annual significant bleeding rates were reported at 3.1–3.4% in patients receiving warfarin, and 2.1–3.6% for those on non-vitamin K antagonist OACs.14)15)16) Moreover, observational data suggest that individuals who undergo successful AF ablation experience notably low stroke rates (<0.7% annually) even after discontinuing OACs.17) Saad et al.’s study18) indicated that both OAC and antiarrhythmic drugs could be discontinued 3 months following CA, irrespective of AF type or baseline CHA2DS2-VASc, in patients with drug-refractory AF. This study observed no significant thromboembolic-related morbidity in patients with CHA2DS2-VASc scores ≤3 who maintained antiplatelet therapy during long-term follow-up.18)

Additionally, Noseworthy et al.19) assessed the impact of discontinuing OAC based on CHA2DS2-VASc scores (after adjusting for other comorbidities) on the risk of cardioembolism. They found that among those at low risk (CHA2DS2-VASc scores of 0 or 1), pausing OAC (defined as at least three months without OAC) did not correlate with an increased risk of embolic events.19) Another study analyzing Danish registries suggested that the bleeding risks associated with continued OAC use beyond three months post-ablation might outweigh the benefits of stroke prevention.20) Furthermore, a systematic review by Romero et al.,21) comparing patients who continued on OAC (ON-OAC group) versus those for whom OAC was discontinued after CA of AF (OFF-OAC group), revealed that patients with a CHA2DS2-VASc ≥2 experienced a significantly decreased thromboembolism (TE) risk and exhibited a favorable net clinical benefit, despite the increased incidence of intracranial haemorrhage in the ON-OAC group. Continuing OAC presented no benefit for patients with a CHA2DS2-VASc ≤1.21) Lastly, a comprehensive AF ablation registry study in Japan by Kanaoka et al.22) examined over 230,000 patients from a nationwide administrative claims database who had undergone CA for AF.

The decision to continue OAC after ablation is influenced by a delicate balance between risks and benefits. Patients with a low calculated risk (CHA2DS2-VASc ≤2) derive no benefit from prolonged OAC usage, yet they face the same risks of bleeding.22)

AF induces a prothrombotic state characterized by platelet activation, elevated coagulation markers, endothelial dysfunction, and abnormal blood flow.23) Following successful CA and the maintenance of sinus rhythm in patients with AF, there is a significant reduction in platelet activation, evidenced by decreased platelet P-selectin and PAC-1 expression. Successfully maintaining sinus rhythm through CA can mitigate the prothrombotic risk associated with AF, primarily due to changes in platelet behavior.24)

The introduction of the cryoballoon represents a recent advancement in technology. Cryoablation generates well-defined lesions and preserves the endothelial cell layer better than conventional RF ablation, which tends to cause more extensive damage to endothelial cells.25) Cryoablation may induce a lesser prothrombotic state, thus potentially allowing for a shorter duration of OAC in patients undergoing both cryoablation and RF ablation. A direct relationship was observed between the extent of RF-induced injury and thrombus volume.25) PVI alone may carry a lower prothrombotic risk compared to more extensive ablation, suggesting that a reduction in OAC duration might also be prudent.

As this was a pilot study and not powered to assess non-inferiority or equivalence, definitive conclusions regarding the safety and efficacy of the one-month anticoagulation cannot be drawn. The absence of events in a cohort of this size underscores the need for a substantially larger study to evaluate this question more conclusively. Notably, the patient population in this study, characterized by young age and low CHA2DS2-VASc scores, inherently carries a low baseline risk of stroke.

As such, strategies to avoid unnecessary anticoagulation in this group are essential, highlighting the potential clinical value of our study.

Our study has several limitations that need consideration. The primary endpoint rate was notably low, rendering the study underpowered to discern a clinically meaningful difference. In the absence of observed strokes and systemic embolism, these findings demand verification or contradiction through more extensive, randomized clinical trials.

Moreover, the lack of blinding in our methodology might have introduced bias among both patients and investigators. Three patients were lost to follow-up. Given the relatively small sample size, a telephone follow-up would have been helpful to capture clinical events more completely.

The overall follow-up rate exceeded 98%. In patients undergoing extensive left atrial ablation, the risk of TE is higher; therefore, shortening anticoagulation duration in such cases may be unsafe, and our findings should not be directly applied to this population.

In carefully selected low-risk patients with paroxysmal AF, shortening OAC duration to 1 month after ablation was feasible and was not associated with thromboembolic events in this pilot study. Larger adequately powered randomized trials are warranted to confirm these findings.

Related articles

PubMed

Comparison of anticoagulation efficacy and safety of different heparin dosages in cardiogenic shock patients supported by intra-aortic balloon pump: A retrospective cohort study.

The study aimed to evaluate whether a half-dose heparin flush strategy during intra-aortic balloon pump (IABP) support improves safety compared with the standard-dose strategy in patients with cardiogenic shock (CS). In this single-center retrospective cohort study, 128 CS patients who received IABP support between January 2023 and December 2024 were included. Sixty-eight patients received a standard-dose heparin flush, and 60 received a half-dose flush. The primary endpoints were clinically rel...

PubMed

Beyond anticoagulation: defining the role of left atrial appendage closure in stroke prevention for atrial fibrillation.

Abstract Oral anticoagulation has a very strong evidence base for stroke prevention in patients with atrial fibrillation (AF) at elevated thromboembolic risk. Direct oral anticoagulants have improved the safety and convenience of treatment, yet important limitations remain, including residual ischaemic stroke, major bleeding, treatment discontinuation, and patient refusal. Left atrial appendage closure (LAAC) offers an alternative strategy for selected patients by excluding the principal anatom...